A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer	Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, esophageal adenocarcinoma, esophageal disorder, gastric neoplasm, neoplasm, stomach disorder	Active, not recruiting	Phase 2	2026-05-15		NCT06251973

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Memorial Sloan Kettering Cancer Center	753

7 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)	Basking Ridge	United States	131
Memorial Sloan Kettering Bergen (Limited Protocol Activities)	Montvale	United States	184
Memorial Sloan Kettering Cancer Center (All Protocol Activities)	New York	United States	230
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)	Middletown	United States	186
Memorial Sloan Kettering Nassau (Limited Protocol Activities)	Uniondale	United States	120
Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities)	Commack	United States	21
Memorial Sloan Kettering Westchester (Limited Protocol Activities)	Harrison	United States	166